Bipartisan efforts to cap the monthly cost of insulin at $35 for individuals with private insurance are gaining traction in Congress. The legislation, which was introduced in March, recently gained additional support from Senators Joni Ernst (R-Iowa), John Hickenlooper (D-Colo.), Kevin Cramer (R-N.D.), and Angela Alsobrooks (D-Md.).
The bill now boasts 22 bipartisan co-sponsors as lawmakers seek solutions to address healthcare affordability. A KFF poll conducted in April highlighted that healthcare costs are a top concern for many Americans. Previously introduced in 2023 with 13 co-sponsors, including seven Republicans, the bill failed to advance out of committee.
The current version of the bill is backed by Democratic Senators Jeanne Shaheen (N.H.), Raphael Warnock (Ga.), and Republicans Susan Collins (Maine) and John Kennedy (La.). It aims to extend the $35 cap for Medicare patients, established under the Inflation Reduction Act, to cover individual plans available on the ObamaCare marketplaces and commercial plans.
Additionally, the bill proposes a pilot grant program in ten states to offer uninsured diabetes patients insulin at the reduced cost of $35 per month. The legislation mandates that group and individual market health plans waive any deductible and limit cost-sharing to no more than $35 or 25% of the list price per month, applicable to at least one insulin type and dosage form.
Legislators intend to attach the insulin price cap measure to must-pass bills slated for the end of the year, including extensions for several healthcare programs.
Additional Health Policy Updates
The Department of Health and Human Services (HHS) announced plans on Monday to increase nutrition education requirements across U.S. medical schools. Eight medical school organizations have committed to enhancing nutrition training at all levels, including competency evaluations, training, and residency programs.
The hemp industry is urging Congress to delay or prevent an impending ban on hemp-derived intoxicants set to take effect in November. The ban, led by Senator Mitch McConnell (R-Ky.), was included in last fall’s government funding bill.
In a separate development, former President Trump announced the expansion of TrumpRx, his administration’s direct-to-consumer drug platform. The initiative now includes an additional 160 prescription drugs, offering discounted prices on over 800 commonly used medications.
Upcoming Legislative Actions
The House Appropriations Committee will convene on Tuesday to assess the FY 2027 HHS funding bill.
State-Level Healthcare News
- State debates intensify over the risks of psychosis and addiction linked to high-potency cannabis.
- The healthcare workforce in Texas has grown by 123% over 30 years, but officials say growth is insufficient to meet demand.
- North Carolina’s State Health Plan board has approved higher costs for certain retirees in 2027.
Health Concerns at National Events
As millions gather for the World Cup in 11 U.S. cities, health experts express concerns over potential measles outbreaks rather than Ebola.
Senator Kennedy shows limited engagement with his expansive health portfolio.
New Medicaid work requirements raise alarms among patient advocates and states.
Stay informed with The Hill’s Health Care newsletter, bringing you crucial updates on how Washington’s decisions affect your health.
Leave a Reply